Details for Patent: RE43932
✉ Email this page to a colleague
Title: | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Abstract: | The invention relates to a new crystalline form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-yl-methyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin- -2-ylamino)phenyl]-benzamide of formula I, which may be used for example for tumour therapy. ##STR00001## |
Inventor(s): | Zimmermann; Juerg (Basel, CH), Sutter; Bertrand (Hesingue, FR), Buerger; Hans Michael (Allschwil, CH) |
Assignee: | Novartis AG (Basel, CH) |
Filing Date: | Sep 21, 2011 |
Application Number: | 13/238,967 |
Claims: | 1. A crystalline form of the monomethanesulfonic acid addition salt of a compound of formula I, ##STR00004## having non-needle-shaped crystals. 2. A crystalline form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I, which comprises at least 95% by weight crystals of the .beta.-modification. 3. A crystalline form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I, which shows on X-ray diffraction a peak at an angle of refraction 2theta of 20.degree., said peak having a relative line intensity of about 65% as compared to the most intense line in the diagram. 4. A pharmaceutical composition, comprising the crystal form according to claim 1 of the methanesulfonic acid addition salt of a compound of formula I and a pharmaceutically acceptable carrier. |